FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to compounds of formula I
and/or to all isomer forms of a compound of formula I and/or to mixtures of these forms in any proportions, and/or to physiologically acceptable salts of the compound of formula I, wherein R1 represents 1) -(C6-C14)-aryl-Z, wherein Z represents aminomethylene, 2) Het-Z, wherein Z represents amino group, and wherein Het is unsubstituted or additionally monosubstituted by group T, R2 represents 1) -(C0)-alkylene-(C6-C14)aryl, wherein aryl is unsubstituted or mono- or disubstituted by group T or 2) -(C0)-alkylene-Het, wherein Het is unsubstituted or monosubstituted by group T, R3 represents 1) -(C0)-alkylene-(C6-C14)-aryl, wherein aryl is unsubstituted or mono- or disubstituted by group T, 2) -O-(C6-C14)-alkylene(C6-C14)-aryl, wherein aryl is unsubstituted or monosubstituted by group T, 3) -(C0)-alkylene-Het, wherein Het is unsubstituted or mono-, di- or trisubstituted by group T, 4) -(C0)-alkylene-(C6-C14)-aryl-Q-(C6-C14)-aryl, wherein both aryl radicals are unsubstituted, 5) -(C0)-alkylene-(C6-C14)-aryl-Q)-Het, wherein aryl and Het in each case are independently unsubstituted or disubstituted by group T, 6) -(C0)-alkylene-Het-Q-Het, wherein both radicals Het are unsubstituted, Q represents a covalent bond, -(C1-C4)-alkylene, -N((C1-C4)-alkyl)- or -O-, T represents 1) halogen, 2) -(C1-C6)-alkyl, wherein alkyl is unsubstituted disubstituted by group -(C1-C3)-fluoralkyl or -N-C(O)-(C1-C4)-alkyl, 3) -(C1-C3)-fluoralkyl, 4) -(C3-C8)-cycloalkyl, 5) -O-(C1-C4)-alkyl, 6) -O-(C1-C3)-fluoralkyl, 7) -N(R10)(R11), wherein R(10) and R(11) independently represent hydrogen atom or -(C1-C6)-alkyl, 8) -C(O)-NH-R10, 9) -SO2-(C1-C4)-alkyl, 10) -SO2-(C1-C3)-fluoralkyl, R4 and R5 are identical and represent hydrogen atom, and R6 represent hydrogen atom with said Het being 5-10-member ring system consisting of 1 or 2 coupled ring systems, and wherein one or two identical or different heteroatoms are selected from oxygen, nitrogen and sulphur. Also, the invention refers to the use of the compound of formula I for preparing a drug.
EFFECT: there are prepared new compounds exhibiting antithrombotic activity, which particularly inhibit blood coagulation factor lXa.
6 cl, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TARTRATE DERIVATIVES APPLIED AS BLOOD COAGULATION FACTOR IXA INHIBITORS | 2007 |
|
RU2446160C2 |
| DERIVATIVES OF BENZIMIDAZOL INHIBITING FACTOR Xa | 2004 |
|
RU2346944C2 |
| AZAINDOL DERIVATIVES AS FACTOR Xa INHIBITORS | 2004 |
|
RU2330853C2 |
| NEW DIAMIDES PYRIMIDIN-4,6 OF DICARBOXYLIC ACID FOR SELECTIVE INHIBITION OF COLLAGENASES | 2003 |
|
RU2344129C2 |
| UREA AND SULPHAMIDE DERIVATIVES AS TAFIA INHIBITORS | 2007 |
|
RU2459619C2 |
| N3-ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | 2003 |
|
RU2300528C2 |
| NOVEL COMPOUNDS AS CATHEPSIN INHIBITORS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, THEIR USING AND METHOD FOR THEIR PREPARING | 2002 |
|
RU2316546C2 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
| DERIVATIVES OF THIOPHENE | 2003 |
|
RU2296758C2 |
| ANTIVIRAL SUBSTRATE ISOSTER ESTERS OF ASPARTATE PROTEASE OR THEIR SALTS, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL PREPARATION AND COMPOSITION | 1995 |
|
RU2164229C2 |
